Imatinib: Novel treatment of immune-mediated kidney injury

Journal of the American Society of Nephrology

Volumn 24, Issue 5, 2013, Pages 694-701

  Wallace, Eric ^a   Gewin, Leslie ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; DENDRITIC CELL; FIBROGENESIS; HUMAN; IMMUNE MEDIATED KIDNEY INJURY; IMMUNE RESPONSE; IMMUNOMODULATION; KIDNEY INJURY; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 84877094679     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012080818     Document Type: Short Survey

References (67)

1. U.S. Renal Data System: UADRAoCKDaESRDitUS. Available at: http://www.usrds.org/qtr/default.aspx. Accessed March 12, 2012
2. Couser WG: Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 23: 381-399, 2012
3. Wang Y, Harris DC: Macrophages in renal disease. J Am Soc Nephrol 22: 21-27, 2011
4. Robinson DR, Wu YM, Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 19: 5548-5557, 2000
5. Hartmann JT, Haap M, Kopp HG, Lipp HP: Tyrosine kinase inhibitors: A review on pharmacology, metabolism and side effects. Curr Drug Metab 10: 470-481, 2009
6. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001 (Pubitemid 32267972)
7. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947-4952, 1997 (Pubitemid 28007210)
8. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, Jarai G: Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 599: 44-53, 2008
9. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, Lyons AB: Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105: 3127-3132, 2005
10. Seggewiss R, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105: 2473-2479, 2005 (Pubitemid 40387048)
11. Wang S, Wilkes MC, Leof EB, Hirschberg R: Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 19: 1-11, 2005 (Pubitemid 40069914)
12. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006 (Pubitemid 44903745)
13. Wallace E, Fogo AB, Schulman G: Imatinib therapy for non-infection- related type II cryoglobulinemia with membranoproliferative glomerulonephritis. Am J Kidney Dis 59: 122- 125, 2012
14. Dwyer JP, Yates KM, Sumner EL, Stone WJ, Wang Y, Koury MJ, Fogo AB, Zent R: Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy. Clin Nephrol 67: 176-181, 2007 (Pubitemid 46416378)
15. Waskow C, Paul S, Haller C, Gassmann M, Rodewald HR: Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. Immunity 17: 277-288, 2002 (Pubitemid 35279549)
16. Agosti V, Corbacioglu S, Ehlers I, Waskow C, Sommer G, Berrozpe G, Kissel H, Tucker CM, Manova K, Moore MA, Rodewald HR, Besmer P: Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J Exp Med 199: 867- 878, 2004
17. Schwartzberg PL, Stall AM, Hardin JD, Bowdish KS, Humaran T, Boast S, Harbison ML, Robertson EJ, Goff SP: Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 65: 1165-1175, 1991 (Pubitemid 121001330)
18. Zipfel PA, Grove M, Blackburn K, Fujimoto M, Tedder TF, Pendergast AM: The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19. J Immunol 165: 6872-6879, 2000 (Pubitemid 32001156)
19. Hardin JD, Boast S, Schwartzberg PL, Lee G, Alt FW, Stall AM, Goff SP: Abnormal peripheral lymphocyte function in c-abl mutant mice. Cell Immunol 172: 100-107, 1996 (Pubitemid 26295668)
20. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH: Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 116: 2633-2642, 2006 (Pubitemid 44511627)
21. Fujimoto M, Poe JC, Inaoki M, Tedder TF: CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol 10: 267-277, 1998 (Pubitemid 28375302)
22. Liberatore RA, Goff SP: c-Abl-deficient mice exhibit reduced numbers of peritoneal B-1 cells and defects in BCR-induced B cell activation. Int Immunol 21: 403-414, 2009
23. Bäckesjö CM, Vargas L, Superti-Furga G, Smith CI: Phosphorylation of Bruton's tyrosine kinase by c-Abl. Biochem Biophys Res Commun 299: 510-515, 2002 (Pubitemid 35365660)
24. Steegmann JL,Moreno G, Aláez C, Osorio S, Granda A, de la Cámara R, Arranz E, Reino FG, Salvanés FR, Fernández- Rañada JM, Muñoz C: Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypo-gammaglobulinemia. Haematologica 88: 762-768, 2003 (Pubitemid 36890110)
25. Cervetti G, Carulli G, Galimberti S, Azzarà A, Cannizzo E, Buda G, Orciuolo E, Petrini M: Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. Leuk Res 32: 191-192, 2008 (Pubitemid 350100829)
26. Santachiara R, Maffei R, Martinelli S, Arcari A, Piacentini F, Trabacchi E, Alfieri P, Ferrari A, Leonardi G, Luppi G, Longo G, Vallisa D, Marasca R, Torelli G: Development of hypo-gammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica 93: 1252-1255, 2008
27. Carulli G, Cannizzo E, Ottaviano V, Cervetti G, Buda G, Galimberti S, Baratè C, Marini A, Petrini M: Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. Leuk Res 34: 1336-1339, 2010
28. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV, Dazzi F: Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18: 1332- 1339, 2004
29. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S: Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104: 1094-1099, 2004 (Pubitemid 39038030)
30. Pribila JT, Shimizu Y: Signal transduction events regulating integrin function and T cell migration: New functions and complexity. Immunol Res 27: 107-128, 2003 (Pubitemid 36349769)
31. Zhang W, Sommers CL, Burshtyn DN, Stebbins CC, DeJarnette JB, Trible RP, Grinberg A, Tsay HC, Jacobs HM, Kessler CM, Long EO, Love PE, Samelson LE: Essential role of LAT in T cell development. Immunity 10: 323-332, 1999 (Pubitemid 29165287)
32. Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, Reuben JM: Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19: 1905-1911, 2005 (Pubitemid 41553998)
33. Gao H, Lee BN, Donato NJ, Talpaz M, Reuben JM: Imatinib (Gleevec, STI-571) suppresses cytokine production by normal T cells activated through T-cell receptor (TCR) signaling. J Allergy Clin Immunol 115: S221, 2005
34. Menke J, Iwata Y, Rabacal WA, Basu R, Stanley ER, Kelley VR: Distinct roles of CSF-1 isoforms in lupus nephritis. J Am Soc Nephrol 22: 1821-1833, 2011
35. Matsumoto K: Production of interleukin-1 in macrophage cultures from rats with nephrotoxic serum nephritis. Int Arch Allergy Appl Immunol 87: 435-438, 1988
36. Tipping PG, Leong TW, Holdsworth SR: Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. Lab Invest 65: 272-279, 1991
37. Boyce NW, Tipping PG, Holdsworth SR: Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. Kidney Int 35: 778-782, 1989 (Pubitemid 19082102)
38. Nishida M, Okumura Y, Fujimoto S, Shiraishi I, Itoi T, Hamaoka K: Adoptive transfer of macrophages ameliorates renal fibrosis in mice. Biochem Biophys Res Commun 332: 11-16, 2005 (Pubitemid 40719450)
39. Le Meur Y, Tesch GH, Hill PA, Mu W, Foti R, Nikolic-Paterson DJ, Atkins RC:Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF/c-fms pathway. J Leukoc Biol 72: 530-537, 2002
40. Lim AK,Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, Tesch GH: Antibody blockade of c-fms suppresses the progression of in fl ammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 52: 1669-1679, 2009
41. Dewar AL, Doherty KV, Hughes TP, Lyons AB: Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol 83: 48-56, 2005 (Pubitemid 40179401)
42. Mack M: Podocyte antigens, dendritic cells and T cells contribute to renal injury in newly developed mouse models of glomerulonephritis. Nephrol Dial Transplant 24: 2984-2986, 2009
43. Appel S, Boehmler AM, Grünebach F, Müller MR, Rupf A, Weck MM, Hartmann U, Reichardt VL, Kanz L, Brümmendorf TH, Brossart P: Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 103: 538-544, 2004 (Pubitemid 38140084)
44. Taieb, J, Maruyama, K, Borg, C, Terme, M & Zitvogel, L: Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 103: 1966-1967; author reply 1967, 2004
45. Zeisberg M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 21: 1819-1834, 2010
46. Klahr S, Morrissey J: Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283: F861-F875, 2002 (Pubitemid 35192452)
47. Wang S, Wilkes MC, Leof EB, Hirschberg R: Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 298: F142-F149, 2010
48. Floege J, Eitner F, Alpers CE: A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 19: 12-23, 2008
49. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59: 1324-1332, 2001 (Pubitemid 32281220)
50. Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper ME: Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 16: 363-373, 2005 (Pubitemid 41725131)
51. Flamant M, Placier S, Rodenas A, Curat CA, Vogel WF, Chatziantoniou C, Dussaule JC: Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease. J Am Soc Nephrol 17: 3374-3381, 2006 (Pubitemid 44865280)
52. Guerrot D, Kerroch M, Placier S, Vandermeersch S, Trivin C, Mael-Ainin M, Chatziantoniou C, Dussaule JC: Discoidin domain receptor 1 is a major mediator of in flammation and fibrosis in obstructive nephropathy. Am J Pathol 179: 83-91, 2011
53. Zoja C, Corna D, Rottoli D, Zanchi C, Abbate M, Remuzzi G: Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 70: 97-103, 2006 (Pubitemid 44000125)
54. Sadanaga A, Nakashima H, Masutani K, Miyake K, Shimizu S, Igawa T, Sugiyama N, Niiro H, Hirakata H, Harada M: Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum 52: 3987-3996, 2005 (Pubitemid 41798238)
55. Iyoda M, Hudkins KL, Becker-Herman S, Wietecha TA, Banas MC, Guo S, Meyer-Bahlburg A, Kowalewska J, Liu G, Ziegler SF, Rawlings DJ, Alpers CE: Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. J Am Soc Nephrol 20: 68-77, 2009
56. Guo S, Kowalewska J, Wietecha TA, Iyoda M, Wang L, Yi K, Spencer M, Banas M, Alexandrescu S, Hudkins KL, Alpers CE: Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. J Am Soc Nephrol 19: 1168-1176, 2008
57. Iyoda M, Shibata T, Kawaguchi M, Yamaoka T, Akizawa T: Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney Int 75: 1060-1070, 2009
58. Savikko J, Rintala JM, Rintala SE, Koskinen PK, von Willebrand E: Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy. Nephrol Dial Transplant 26: 3026-3032, 2011
59. Iyoda M, Shibata T, Hirai Y, Kuno Y, Akizawa T: Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. J Am Soc Nephrol 22: 1486-1496, 2011
60. Savikko J, Rintala J, von Willebrand E: Early short-term platelet-derived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation. Transplant Proc 38: 3231-3232, 2006 (Pubitemid 44908467)
61. Savikko J, Taskinen E, Von Willebrand E: Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: Tyrosine kinase inhibitors as a potential therapy. Transplantation 75: 1147-1153, 2003 (Pubitemid 36513012)
62. Magro F, Costa C: Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. Inflamm Bowel Dis 12: 1087-1089, 2006 (Pubitemid 44665480)
63. Pereira I, Fialho S, Castro G, Zimmermann A: Imatinib mesylate induces clinical remission in rheumatoid arthritis. Joint Bone Spine 77: 372-373, 2010
64. Tamaki Z, Asano Y, Hatano M, Yao A, Kawashima T, Tomita M, Kinugawa K, Nagai R, Sato S: Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. Mod Rheumatol 22: 94-99, 2012
65. Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 70: 1003-1009, 2011
66. Kay J, High WA: Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 58: 2543-2548, 2008
67. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR; Imatinib-IPF Study Investigators: Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 181: 604-610, 2010